MCM
DRNA

Moore Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Moore Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-164,596
Closed -$2.36M – 371
2019
Q3 		$2.36M Buy
+164,596
New +$2.35M 0.09% 200

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Moore Capital Management's DRNA Position: Q4 2019 in Review

Moore Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2019, closing a stake of 164,596 shares — an estimated $2.36M sold.

Moore Capital Management first reported a position in DRNA in Q3 2019 and held it in 1 quarter. The position peaked at $2.36M in Q3 2019. 169 funds tracked by Wall St. Rank hold DRNA as of Q4 2019.

  • Moore Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Moore Capital Management sold 164,596 Dicerna Pharmaceuticals, Inc. shares in Q4 2019, an estimated $2.36M.
  • Moore Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Moore Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $2.36M in Q3 2019.
  • 169 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2019.

Based on Moore Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.